| Today’s Big NewsFeb 22, 2024 |
| By Kevin Dunleavy In the fall vaccination season, Moderna captured 48% of the COVID-19 retail market in the United States versus a 37% showing in 2022, closing the gap on Pfizer’s Comirnaty. Spikevax revenue for the quarter came to $2.8 billion, topping analyst expectations of $2.5 billion. |
|
|
|
By Max Bayer After Moderna's COVID sales landed at the low end of the company's 2023 estimates, investors' attention is turning toward other late-stage programs and near-commercial products, namely RSV and CMV. The FDA is slated to decide on the company's RSV vaccine by the middle of May. |
By Andrea Park In the wake of a full-year earnings sheet that showed an 8% year-over-year drop in revenues and a major slump in operating income that sent its net earnings into the red, QuidelOrtho is making some changes at the top. |
By Fraiser Kansteiner To get a pulse on Moderna following its “year of transition” in 2023, look no further than the company’s manufacturing operations. The Cambridge, Massachusetts-based biotech has incurred a COVID-related wind-down charge on one hand, while it spends millions of dollars to bolster cancer vaccines at the same time. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Annalee Armstrong AbbVie is wrapping its tentacles around a few more oncology and immunology candidates thanks to a new $64 million deal with Tentarix Biotherapeutics. |
By Andrea Park After nearly a decade in the role, Agilent Technologies CEO Mike McMullen is stepping down. |
By Fraiser Kansteiner Novavax has reached a settlement with Gavi, the Vaccine Alliance ending arbitration tied to a 2021 advance purchase agreement around its prototype COVID-19 vaccine NVX-CoV2373. Had Novavax lost the arbitration, the company might have had to refund nearly $700 million. |
By Gabrielle Masson ORI Capital has raised $260 million, the VC’s second life sciences fund that will go toward early-stage biotechs worldwide. |
By Conor Hale The shoulder green light marks the fourth in Zimmer’s family of Rosa robotic helpers, after go-aheads in total knee and hip replacements. |
By Gabrielle Masson The pace of clinical trial starts is leveling out, dropping below pre-pandemic highs with a 15% decline in 2023 compared to the year before. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics. |
|
|---|
|
|
|
Wednesday, March 13, 2024 | 11:00am ET/ 8:00am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion! 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
